Arbutus Biopharma Gestione
Gestione criteri di controllo 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Mike McElhaugh
Amministratore delegato
US$1.6m
Compenso totale
| Percentuale dello stipendio del CEO | 29.8% |
| Mandato del CEO | 2yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 3.2yrs |
| Durata media del Consiglio di amministrazione | 6.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$77m |
| Jun 30 2024 | n/a | n/a | -US$77m |
| Mar 31 2024 | n/a | n/a | -US$74m |
| Dec 31 2023 | US$2m | US$483k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$70m |
| Dec 31 2022 | US$1m | US$449k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | n/a | n/a | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$87m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$1m | US$415k | -US$76m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 1.62M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.17M ).
Compensazione vs guadagni: La retribuzione di Mike è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Mike McElhaugh (50 yo)
2yrs
Mandato
US$1,620,485
Compensazione
Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 2yrs | US$1.62m | Nessun dato | |
| Chief Scientific Officer | 9.8yrs | US$1.61m | 0.79% $ 5.2m | |
| CFO & Chief Accounting Officer | 6.4yrs | US$1.46m | 0.0088% $ 58.7k | |
| Vice President of Investor Relations | 3.2yrs | Nessun dato | Nessun dato | |
| General Counsel | 1.3yrs | Nessun dato | Nessun dato | |
| Vice President of Human Resources | no data | Nessun dato | Nessun dato | |
| Chief Medical Officer | 1.3yrs | Nessun dato | 0.0028% $ 18.5k | |
| Corporate Secretary | 14.5yrs | Nessun dato | Nessun dato |
3.2yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di ABUS è considerato esperto (durata media dell'incarico 3.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | less than a year | US$1.62m | Nessun dato | |
| Independent Non-Executive Director | 9.9yrs | US$174.24k | 0.00053% $ 3.5k | |
| Independent Director | 7.7yrs | US$161.74k | 0% $ 0 | |
| Independent Non-Executive Director | 9.7yrs | US$156.74k | 0.024% $ 161.7k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.1yrs | US$176.74k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 6.1yrs | Nessun dato | Nessun dato | |
| Independent Chairman of the Board of Directors | 6yrs | US$187.99k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
6.1yrs
Durata media
57.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABUS sono considerati esperti (durata media dell'incarico 6.1 anni).